Communicate with Supplier? Supplier
Amy Cheng Ms. Amy Cheng
What can I do for you?
Chat Now Contact Supplier
Taizhou Volsen Chemical Co., Ltd.
HomeNewsMirogabalin

Mirogabalin

2019-11-14
New medicine for peripheral neuralgia! The first three totals of Tarlige (mirogabalin) were approved for the treatment of peripheral neuropathic pain (PNP)

January 17, 2019 / Bio Valley BIOON / -- Daiichi Sankyo, the Japanese Pharmaceutical company, recently announced that Tarlige (mirogabalin besylate) 2.5mg, 5mg, 10mg, 15mg tablets have been approved in Japan for the treatment of peripheral neuropathic pain (PNP).In general, an adult patient's initial dose is 5 mg, taken orally twice a day, and then gradually increased by 5 mg to 15 mg at intervals of at least one week The dose can be appropriately adjusted between 10 mg and 15 mg depending on the age and symptoms, and taken orally twice a day for one week.
The active pharmaceutical ingredient of Tarlige is mirogabalin, an α2δ ligand created by the first three,By oral administration, the α2δ-1 subunit of voltage-dependent calcium channels (1 and 2) can be preferentially and selectively bound, but the potency is significantly higher than that of pregabalinThese calcium channels are widely present in the nervous system that mediates pain transmission and management in various regions of the body. mirogabalin has unique binding properties and long-acting effects.Mirogabalin belongs to the class of drugs called gabapentinoid, which is the same as gabapentin and pregabalin.
The first three submitted a new drug application for Tarlige in February 2018.The drug was approved based on a phase III clinical study in patients with diabetic peripheral neuropathic pain (DPNP) and positive data from a phase III clinical study in patients with postherpetic neuralgia (PHN).Both studies were conducted in Asia, including Japan.
In the first three, Tarlige is expected to provide Japanese patients and healthcare professionals with an innovative treatment for peripheral neuropathic pain (PNP).PNP is caused by peripheral nerve damage or dysfunction caused by various causes. Typical PNPs include diabetic PNP (DPNP) and post-herpetic neuralgia (PHN).

DPNP and PHN are typical examples of PNP caused by nerve damage.DPNP is a disease that causes neuropathy and numbness in the extremities and is one of the most common long-term complications of diabetes. nerve damage.Symptoms include severe pain, hyperalgesia, numbness, balance and impaired muscle movement, burning and stinging.Pain often worsens at night and can cause sleep disorders.In Japan, it is estimated that there are more than 10 million diabetic patients, and 9-22% of patients report DPNP.
The onset of herpes zoster is caused by a decrease in immunity to the varicella-band acne virus, which forms a latent infection in the ganglion .In PHN, even after the cure for herpes zoster, the burning pain or the pain that penetrates the body like electricity still exists. The disease is considered to be a kind of intractable pain, which can cause muscle weakness and can cause paralysis in rare cases.In Japan, between 500,000 and 600,000 people suffer from herpes zoster every year, and 10-25% of them suffer from PHN.

Previous: Intravenous Inhalation Powder For Indacaterol Maleate

Next: CPhi Frankfurt 2019